Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00632541 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
A Phase 2 study, sponsored by Hoosier Cancer Research Network.
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT00632541 is a Phase 2 study that was terminated before completion, run by Hoosier Cancer Research Network. The registered enrollment target is 18 participants.
The verdict
NCT00632541, a Phase 2 study, was terminated before completion, sponsored by Hoosier Cancer Research Network.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
Prior clinical trials involving bevacizumab and sorafenib have demonstrated single agent activity in previously treated advanced breast cancer. This trial will test combined VEGF inhibition with sorafenib and bevacizumab in less heavily pre-treated patients with advanced breast cancer.
Interventions
- DRUG Bevacizumab
- DRUG Sorafenib
- OTHER Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00632541
The ClinicalTrials.gov registry entry for NCT00632541 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoosier Cancer Research Network, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT00632541 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00632541 about?
NCT00632541 is a clinical study titled "A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer". Prior clinical trials involving bevacizumab and sorafenib have demonstrated single agent activity in previously treated advanced breast cancer. This trial will test combined VEGF inhibition with sorafenib and bevacizumab in less heavily pre-treated patients with advanced breast cancer.
What is the current status of trial NCT00632541?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2007-10. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00632541?
The interventions under investigation include: Bevacizumab (DRUG), Sorafenib (DRUG), Imaging (OTHER).
Who is sponsoring clinical trial NCT00632541?
This trial is sponsored by Hoosier Cancer Research Network, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.